Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.73 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.73 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | HRH1 | P35367 | 1/20 | 0.73 |
| ▸ | DRD3 | P35462 | 1/20 | 0.73 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.73 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.73 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.63 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.63 |
| ▸ | CA2 | P00918 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.60 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.60 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1943942 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1115851 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| Arundic Acid SCHEMBL3450562 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL3630645 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL2489255 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1115797 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL15499898 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL432094 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1115939 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1115977 | 1.00 | CHRM1 (0.73) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 651 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2025-02-20 | — | — | US | claimed |
| CN-116060124-B | Oil-soluble organic metal salt composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-116060130-B | Organic molybdenum salt composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-116060125-B | Cobalt-molybdenum bimetal organic salt composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-115151534-B | Inhibitors of interleukin-1 receptor associated kinase (IRAK)/FMS-like receptor tyrosine kinase (FLT 3), pharmaceutical products thereof and methods of use thereof | 南京药石科技股份有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-2381797-B2 | ANIMAL FEED ADDITIVE AND ANIMAL FEED COMPRISING ALKYL ESTERS OF MEDIUM CHAIN FATTY ACIDS, AND THEIR USE IN ANIMAL FEED | NUTRECO NEDERLAND BV (NL) | 2023-05-31 | — | — | EP | claimed |
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | UCL BUSINESS LTD (GB) | 2023-05-11 | — | — | US | claimed |
| CN-116060130-A | Organic molybdenum salt composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-116060124-A | Oil-soluble organic metal salt composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-116060125-A | Cobalt-molybdenum bimetal organic salt composition and preparation method and application thereof | 中国石油化工股份有限公司 | 2023-05-05 | — | — | CN | claimed |
| CN-1309652-A | Intermediates and process for preparation of optically active octanoic acid derivs. | ONO PHARMACEUTICAL CO (JP) | 2001-08-22 | — | — | CN | claimed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| EP-1078921-A1 | NOVEL INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF OPTICALLY ACTIVE OCTANOIC ACID DERIVATIVES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| CN-1100408-A | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1995-03-22 | — | — | CN | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| EP-0368406-B1 | COMPOSITIONS FOR THE TRANSDERMAL DELIVERY OF PHARMACEUTICAL ACTIVES | Norwich Eaton Pharmaceuticals, Inc. (US) | 1993-07-28 | — | — | EP | claimed |
| US-4272511-A | POLYMER OF VINYLPYRROLIDONE, VINYL ACETATE, CROTONIC ACID AND AT LEAST ONE OTHER MONOMER | L'OREAL (FR) | 1981-06-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230146709-A1 | THERAPEUTIC USE OF COMPOUNDS | SGMS1, CHRM1, CYP11B1 | CHRM1 2/4885AKR1A1 134/4885CHRM3 120/4885 |
| US-20250057798-A1 | THERAPEUTIC USE OF COMPOUNDS | CYP11B1, SGMS1, PTGER1 | CHRM1 5/4885AKR1A1 86/4885CHRM3 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.